Walder Wyss advised SixPeaks Bio AG while Lenz & Staehelin acted as Swiss counsel to AstraZeneca. SixPeaks Bio AG has secured USD30 million in Series A...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on this transaction. ierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer...
You must be a Standard 1 Year member to access this content.
Walder Wyss advises Alentis Therapeutics on the financing. Alentis Therapeutics has announced $105 million in Series C financing. The funding round was led by Jeito Capital...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised the buyer in this transaction. A group of entrepreneurs advised by Nachfolgepartner AG acquires all shares in iPet.ch GmbH (iPet.ch), the largest online...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised BC Platforms on the deal. BC Platforms announced a USD 20m growth financing led by Jolt Capital. BC Platforms is a global leader in...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on the deal. Versant Ventures announced the debut of Vector BioPharma, a biopharmaceutical company developing a precision gene delivery platform that...
You must be a Standard 1 Year member to access this content.
MLLStart! advised Clinical Research Ventures. Walder Wyss advises BioVersys. BioVersys AG, a privately-held clinical-stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for...
You must be a Standard 1 Year member to access this content.
Lenz & Staehelin advised co-lead investors Samsara Biocapital and Lightspeed Venture Partners as their Swiss counsel. VISCHER advised ImmunOs. Walder Wyss advises Gimv. ImmunOs Therapeutics AG,...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Engimmune Therapeutics on the deal. Vischer advised the investors Pureos Bio-ventures and Novo Holdings. Engimmune Therapeutics completed a CHF 15.5m seed financing round co-led...
You must be a Standard 1 Year member to access this content.
Freshfields Bruckhaus Deringer has advised International Chemical Investors Group on the deal, while Walder Wyss and Latham & Watkins advised Astorg. Milbank advised the management of...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on the deal. VISCHER advised Cimeo Therapeutics. Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel...
You must be a Standard 1 Year member to access this content.
